Head and Neck Cancer Trial, Recruiting (NCT03975322)

Head and Neck Cancer Trial, Recruiting NCT03975322 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Head and Neck Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT03975322 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Head And Neck Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 80 years old
Both men and women are eligible
People who have been diagnosed with one or more white patches (leukoplakia) in the mouth, including cases where the white patches are linked to a condition called lichen planus, OR are linked to an immune system disease or a weakened immune system, OR are linked to a history of cancer somewhere else in the body (not including the mouth)
People who have given their agreement to take part in the study after being fully informed about it

Who may not be able to join:

People who have signs of an active invasive cancer in the mouth
People who have a history of mouth cancer
People who are not able to give informed consent themselves
People who have been assessed as not suitable by the trial team (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Manuel Weber, MD, DMD, Maxillofacial Surgery Erlangen

Phone: 0049 9131 85 43749

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03975322

Sponsor: University of Erlangen-Nürnberg Medical School

Phase: Not Applicable

Status: Recruiting

Condition: Head and Neck Cancer

Trial contact: 0049 9131 85 43749

More information: https://clinicaltrials.gov/study/NCT03975322

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 80 years old
Both men and women are eligible
People who have been diagnosed with one or more white patches (leukoplakia) in the mouth, including cases where the white patches are linked to a condition called lichen planus, OR are linked to an immune system disease or a weakened immune system, OR are linked to a history of cancer somewhere else in the body (not including the mouth)
People who have given their agreement to take part in the study after being fully informed about it

Who may not be able to join:

People who have signs of an active invasive cancer in the mouth
People who have a history of mouth cancer
People who are not able to give informed consent themselves
People who have been assessed as not suitable by the trial team (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Erlangen-Nürnberg Medical School

Registry

ClinicalTrials.gov

Start date

1 December 2019

Est. completion

30 December 2024

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Dependence of malignant transformation on a MAGE-A based immunoscore; Dependence of malignant transformation on a MAGE-A based immunoscore; Dependence of malignant transformation on a MAGE-A based immunoscore

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov